4D Molecular Therapeutics Inc. has filed to raise up to $100 million in an IPO.

ADC Therapeutics SA said it withdrew its proposed IPO, citing adverse market conditions.

Adicet Bio Inc. raised $80 million from a series B round.

Aeovian Pharmaceuticals said it closed a $37 million series A round.

Aprea Therapeutics Inc. said it priced its IPO of approximately 5.7 common shares at $15 apiece, the midpoint of its proposed range, for expected gross proceeds of approximately $85 million.

Arcellx Inc. raised $85.7 million in a series B round.

Cabaletta Bio Inc. has filed to raise up to $100 million in an IPO.

Constellation Pharmaceuticals Inc. said it entered a securities purchase agreement with investors for the private placement of $65 million.

Frequency Therapeutics Inc. priced its IPO of 6 million common shares at $14 apiece, the low end of its proposed range, for expected gross proceeds of approximately $84 million.

GI Innovation Inc., a microbiome combination drug developer, has recently issued fully paid convertible preferred stock worth KRW37.5 billion (US$31 million) for a series B investment.

Mesoblast Ltd. has completed an AU$75 million (US$50.32 million) capital raising via an oversubscribed placement to existing and new Australian and global institutional investors.

Monopar Therapeutics Inc. said it postponed its planned IPO, citing market conditions.

Phathom Pharmaceuticals Inc. has filed to raise up to $100 million in an IPO.

Stipe Therapeutics said it received €20 million (US$21.95 million) from a series A financing.

Tenaya Therapeutics Inc. raised $92 million in a series B round.

Viela Bio Inc. said it priced its IPO of 7.9 million common shares at $19 apiece, the low end of its proposed range, expecting to raise approximately $150 million.

Vir Biotechnology Inc. has established terms for its proposed IPO, planning to offer 7.14 million shares at a price range of $20 to $22.


Applied Genetic Technologies Corp. and Otonomy Inc. said they entered a strategic collaboration to co-develop and co-commercialize an AAV-based gene therapy to restore hearing in patients with sensorineural hearing loss caused by a mutation in the gap junction protein beta 2 gene.

Aslan Pharmaceuticals Pte. Ltd. and Bukwang Pharmaceutical Co. Ltd. said they established a new joint venture to develop preclinical aryl hydrocarbon receptor antagonists from Aslan's early stage pipeline.

Currax Pharmaceuticals LLC acquired Nalpropion Pharmaceuticals Inc., giving Currax worldwide rights to Contrave (naltrexone HCl and bupropion HCl extended release), a prescription weight loss medicine. Goldfinch Bio Inc. said it entered a license agreement with Takeda Pharmaceutical Co. Ltd. for worldwide rights to a preclinical, peripherally restricted cannabinoid receptor 1 monoclonal antibody.

Newlink Genetics Corp. and Lumos Pharma Inc. agreed to merge, with the deal expected to close in the first quarter of 2020. Lumos will become a wholly owned subsidiary of Newlink, which will be renamed Lumos Pharma Inc.

Puretech Health plc acquired the remaining 10% minority interests in Ariya Therapeutics Inc., which has been renamed Puretech LYT Inc.

Simcere Pharmaceutical Group and JW Pharmaceutical Corp. signed a collaboration and exclusive license agreement for gout drug candidate URC-102 in China, including Chinese Hong Kong and Macao.

Swedish Orphan Biovitrum AB is acquiring Dova Pharmaceuticals Inc. in a deal worth about $915 million.

Takeda Pharmaceutical Co. Ltd. will use Boston-based Cerveau Technologies Inc.'s MK-6240, an investigational imaging agent, in PET scans to assess the status and progression of neurofibrillary tangles in the brain.

Tmunity Therapeutics Inc. licensed a CAR T therapy targeting glypican 2 for the treatment of neuroblastoma from Children's Hospital of Philadelphia.

Viscient Biosciences Inc., a company working at the intersection of 3D tissue technology and transcriptomics technology to discover and develop drugs across a range of therapeutic areas, said it has submitted a merger proposal to Organovo Holdings Inc.'s board to combine the two companies.

...And more

Australia is at risk of falling behind the U.S. and Europe in preventing recurrence of melanoma, the Melanoma Institute Australia warns. It is urging the Australian government to undertake a timely review of immunotherapy treatments effective in preventing the spread of melanoma and to fast track listings on the government-subsidized Pharmaceutical Benefits Scheme.

Eli Lilly and Co. has requested the delisting of its shares from Euronext Paris due to the very low trading volume, costs and administrative requirements related to its secondary listing on Euronext Paris.

Haliodx SAS joined the Oncobiome consortium to link biomarkers in the group's effort to determine the relationship between intestinal microbial signatures and the response, resistance and toxicity induced by breast, colon, lung and skin cancer treatments.

Relmada Therapeutics Inc. said its board approved a 1-for-4 reverse stock split in preparation for its proposed listing of its common stock on Nasdaq.

Ubiome Inc. has requested that the Bankruptcy Court presiding over its pending Chapter 11 bankruptcy convert its case to a liquidation under Chapter 7 of the U.S. Bankruptcy Code.

Under the "Healthy China" campaign, China has introduced a three-year action plan for preventing and treating cancer. The plan vows to speed up the marketing of cancer drugs in the country, even aiming for simultaneous marketing with other countries.

No Comments